Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-R
- Development stage
- Unknown
- Lead developer
- Kaiser Medical Clinic
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bio-R (also known as Bio-RD) is a branded generic pharmaceutical product developed and marketed by Kaiser Pharmaceuticals. It contains domperidone as its active ingredient, which is a small molecule dopamine D2 receptor antagonist. Domperidone works by blocking dopamine receptors in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) located in the area postrema. Because it does not readily cross the blood-brain barrier, it primarily exerts peripheral effects, such as increasing gastrointestinal motility and gastric emptying, while providing antiemetic relief. It is used to treat nausea, vomiting, and gastrointestinal motility disorders.
- Brand names
- Bio-RBio-RD
- Other names
- domperidone
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on Bio-R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-R.